ARVO

Palatin Technologies reveals groundbreaking preclinical results on melanocortin agonists, showcasing their potential to combat diabetic retinopathy and preserve vision.

At ARVO 2025, in Salt Lake City, Utah, Diana Do, MD, gave an update on the LIGHTSITE III study of photobiomodulation for dry age-related macular degeneration.

Giullia Coradetti, MD, offered insight into her research on a post-hoc analysis based on the GATHER 2 clinical trial data for geographic atrophy and age-related macular degeneration.

A recent analysis reveals that ellipsoidal zone-retinal pigment epithelial thickness predicts future visual loss in geographic atrophy patients, highlighting early intervention opportunities.

Christina Prescott, MD, talks about the rate of recurrence of stromal keratitis in the Zoster Eye Disease Study, both in the placebo and in the treatment group.

Ellen Koo, MD, presented data from first in-human clinical trials, looking at the results from magnetic cell therapy and reports on the efficacy and safety in the patients.

Perfuse Therapeutics reveals promising results for PER-001, a groundbreaking glaucoma treatment, enhancing vision and ocular health in clinical trials.

Alkeus Pharmaceuticals reveals promising Phase 2 SAGA study results, showing gildeuretinol slows vision decline in geographic atrophy linked to AMD.

Beacon Therapeutics reveals promising interim results for laru-zova, a gene therapy showing potential to improve vision in XLRP patients.

A one-drop, low dose atropine study assesses accommodative amplitude and dynamics, with clinically applicable findings.

Topcon Healthcare launches IDHea, an innovative platform enhancing AI research and ocular data access to improve clinical outcomes in healthcare.

Isarna Therapeutics reveals promising Phase 2 BETTER trial results for ISTH0036, a potential breakthrough in treating retinal fibrosis.

A study reveals that repeated anti-VEGF injections for AMD do not alter retinal vascular metrics over time, ensuring treatment stability.

Katherine Talcott, MD, a retina specialist at Cleveland Clinic, presented findings on EYP-1901 in the phase 2 DAVIO study.

The trial will assess allogeneic retinal pigment epithelium cells in the treatment of geographic atrophy.

Opus Genetics reveals promising 1-year results from OPGx-LCA5 gene therapy, showing sustained vision improvements in adults with LCA5 retinal degeneration.

UNITY Biotechnology reveals promising 36-week results for UBX1325 in treating diabetic macular edema, showing non-inferiority to aflibercept and strong safety profile.

Researchers stratified a dataset of more than 100 patients in an emergency department to see which patients may be indicated for retinal artery occlusions.

At the ARVO 2025 Annual Meeting in Salt Lake City, Utah, Nimesh Patel, MD, presented on the LUCIA and LUGANO phase 3 pivotal trials for EYP-1901 against aflibercept for the treatment of wet macular degeneration.

At the ARVO 2025 meeting in Salt Lake City, Utah, Cameron Cummings presented a poster on how retinal microvascular imaging metrics may show sex-specific biomarkers for Parkinson's disease.

Roshan Kenia presented a poster on how AI-CNet3D enhances glaucoma classification using cross-attention networks while improving interpretability and performance in OCT scan analysis.

Dr. Subrata Batabyal earns the 2025 Carl Camras Award for innovative optogenetic therapies, advancing vision restoration for inherited retinal diseases.

Discover groundbreaking research and presentations from leading companies at the ARVO 2025 Annual Meeting, advancing ophthalmology and patient care.

The company announced 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting from May 4 to 8 in Salt Lake City, Utah.

The annual ARVO meeting will be held in Salt Lake City, Utah and feature presentation on clinical trials from around the globe.

The findings of this model support KIO-104 as a promising therapeutic candidate for both the prevention and treatment of PVR.

Maria Vittoria Cicinelli, MD, Denise Loya-Garcia, MD, PhD, and Vishal Raval, MD, were announced as the recipients and will receive a $3,000 honorarium.